ARCHIVES

Nobel Laureate Gilman Prepares to Leave The Texas Cancer Agency—Can it Survive?

This article is from The Cancer Letter archive.

Vol. 38 No. 36 | September 28, 2012

Download PDF Visit The Full Archive

Related Articles

Phase III Data of Antibody-Drug Conjugate Shows PFS Increase in HER2+ Disease

June 29, 2012

HRSA: Discounts Owed on Some Orphan Drug Uses

October 24, 2014

Centers Urged To Apply For Comprehensive Status By June 1

February 16, 1990

Breast Cancer Low Fat Investigators to Seek R01 Funds for New Compliance, Biochemical Studies

April 25, 1986

Final Issue Of the Year

December 14, 1990

NCAB Approves CCP, Agrees To Compromise On Including Control

May 21, 1982